Susanne Kintscher conducted her PhD at the German Cancer Research Center in Heidelberg, Germany in the research area of therapeutic targeting of Human Papillomaviruses. She joined Miltenyi in 2011 and currently, as a lead for the MS&T team for lentiviral vector manufacturing for ex-vivo gene therapies, she is working with her colleagues to drive process validation strategies toward marketing authorization approval. Her focus is on translating process knowledge into GMP manufacturing in the challenging field of enhanced validation approaches and regulatory requirements for ATMPs.